Lung-MAP Infographics Illustrate How the Trial is Helping Patients

Both AstraZeneca and MedImmune are pleased to join our partners as part of this exciting new paradigm in oncology drug development. One of our key company priorities is to bring innovative new treatments to patients in need as quickly as possible. Lung-MAP is unique, as it will expand options and ultimately help improve treatment outcomes by identifying the targeted therapies best suited to meet the specific needs of patients with non-small cell lung cancer, one of the deadliest cancers.